AdaptHealth names new CFO as incumbent departs, leaving strategy unchanged but transition costs

This is a leadership reset, not an operating update. AdaptHealth names Harriss Currie CFO effective September 9, while Jason Clemens loses CFO authority at the close of business September 8 and remains employed only through October 1. The filing offers no revenue, EBITDA, guidance, or strategic change to re-underwrite. 〔0〕

The incoming CFO brings credible large-company finance experience, but the filing does not explain the departure. Currie spent more than 15 years as CFO of Luminex before its sale to DiaSorin, though his more recent roles were shorter and spread across several healthcare and technology businesses. That makes the appointment directionally reassuring on finance experience, but not enough to establish a clear operating or strategic improvement. 〔1〕

The handoff reduces near-term execution risk, while the unexplained CFO exit keeps the signal two-sided. Clemens will assist through October 1, giving the company roughly three weeks of transition coverage, but the filing provides no reason for his termination or indication that performance expectations, controls, or financial reporting changed. 〔2〕

The economics are meaningful but routine for a public-company CFO. Currie receives a $670,000 base salary, a 100% target annual bonus, an initial $818,462 restricted-stock grant, and the current intent—without a contractual entitlement—to provide annual equity awards valued at $2.66 million beginning in 2027. Those terms add compensation and dilution exposure, but the filing gives no basis to call them unusually aggressive.

Net read: mixed because continuity is protected, but the reason for the change remains undisclosed. With no published operating benchmark or guidance change in the filing, this cannot be scored as a beat or miss; the market is left weighing an experienced replacement and orderly transition against an unexplained CFO departure and added compensation commitments.